Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 2/2017

19.10.2016 | Editorial

Radioiodine – the success story of Nuclear Medicine

75th Anniversary of the first use of Iodine-131 in humans

verfasst von: V. Ralph McCready

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Excerpt

This year marks the 75th anniversary since Saul Hertz first administered radioiodine (I-130–I-131) to a patient on January 1st 1941 in the Massachusetts General Hospital as a treatment for hyperthyroidism. It followed his previous studies on animal thyroid physiology with I-128 to discover how radioiodine could be administered to have a maximal radiation effect in hyperthyroidism. In May 1946, Hertz and Roberts published the follow-up of their series of 29 patients treated with radioactive iodine for hyperthyroidism [1]. …
Literatur
1.
Hertz S, Roberts A. Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism. J Am Med Assoc. 1946;131:81–6.CrossRef
2.
Mazzaferri E. A randomized trial of remnant ablation--in search of an impossible dream? J Clin Endocrinol Metab. 2004;89(8):3662–4.CrossRef
3.
Webb S. From the watching of shadows: the origins of radiological tomography. 1990.: Bristol New York: Adam Hilgey. 1990.
4.
Smithers DW. Some varied applications of radioactive isotopes to the localization and treatment of tumors. Acta Radiol. 1951;35(1):49–61.CrossRef
5.
Siegel E. The beginnings of radioiodine therapy of metastatic thyroid carcinoma: a memoir of Samuel M. Seidlin, M. D. (1895–1955) and his celebrated patient. Cancer Biother Radiopharm. 1999;14(2):71–9.CrossRef
6.
Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941–59.CrossRef
7.
Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674–85.CrossRef
8.
Comtois R, Theriault C, Del VP. Assessment of the efficacy of iodine-131 for thyroid ablation. J Nucl Med. 1993;34(11):1927–30.
9.
Welsh L, Powell C, Pratt B, Harrington K, Nutting C, Harmer C, et al. Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer. J Clin Endocrinol Metab. 2013;98(5):1819–25.CrossRef
10.
Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117(19):4439–46.CrossRef
11.
Hirsch D, Shohat T, Gorshtein A, Robenshtok E, Shimon I, Benbassat C. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer. Thyroid. 2016;26(8):1110–6.CrossRef
12.
Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–9.CrossRef
13.
Mallick U, Harmer C, Hackshaw A, Moss L. Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo. Clin Oncol (R Coll Radiol). 2012;24(3):159–61.CrossRef
14.
Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K, et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37(2):270–5.CrossRef
15.
Wierts R, Brans B, Havekes B, Kemerink GJ, Halders SG, Schaper NN, et al. Dose–response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT. J Nucl Med. 2016;57(7):1027–32.CrossRef
16.
Jentzen W, Verschure F, van ZA, van de KR, Wierts R, Schmitz J, et al. Response Assessment of Bone Metastases from Differentiated Thyroid Cancer Patients in the Initial Radioiodine Treatment Using Iodine-124 PET Imaging. J Nucl Med. 2016.
17.
Franzius C, Dietlein M, Biermann M, Fruhwald M, Linden T, Bucsky P, et al. Procedure guideline for radioiodine therapy and 131iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer. Nuklearmedizin. 2007;46(5):224–31.CrossRef
18.
Wang J, Qin L. Radioiodine therapy versus antithyroid drugs in Graves’ disease: a meta-analysis of randomized controlled trials. Br J Radiol. 2016:20160418.
19.
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and other causes of Thyrotoxicosis. Thyroid. 2016.
20.
Stokkel MP, Handkiewicz JD, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37(11):2218–28.CrossRef
21.
Reiners C, Schneider P. Radioiodine therapy of thyroid autonomy. Eur J Nucl Med Mol Imaging. 2002;29 Suppl 2:S471–S8.CrossRef
22.
Aktas GE, Turoglu HT, Erdil TY, Inanir S, Dede F. Long-Term Results of Fixed High-Dose I-131 Treatment for Toxic Nodular Goiter: Higher Euthyroidism Rates in Geriatric Patients. Mol Imaging Radionucl Ther. 2015;24(3):94–9.CrossRef
23.
McCready VR, Dizdarevic S, Aplin M. Interventional nuclear medicine. Eur J Nucl Med Mol Imaging. 2013;40(7):1044–6.CrossRef
24.
Happel C, Korkusuz H, Koch DA, Grunwald F, Kranert WT. Combination of ultrasound guided percutaneous microwave ablation and radioiodine therapy in benign thyroid diseases. A suitable method to reduce the 131I activity and hospitalization time? Nuklearmedizin. 2015;54(3):118–24.CrossRef
25.
Sung JY, Baek JH, Jung SL, Kim JH, Kim KS, Lee D, et al. Radiofrequency ablation for autonomously functioning thyroid nodules: a multicenter study. Thyroid. 2015;25(1):112–7.CrossRef
Metadaten
Titel
Radioiodine – the success story of Nuclear Medicine
75th Anniversary of the first use of Iodine-131 in humans
verfasst von
V. Ralph McCready
Publikationsdatum
19.10.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3548-5

Weitere Artikel der Ausgabe 2/2017

European Journal of Nuclear Medicine and Molecular Imaging 2/2017 Zur Ausgabe

Original Article

Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma

Original Article

Characterization of [11C]Lu AE92686 as a PET radioligand for phosphodiesterase 10A in the nonhuman primate brain

Review Article

Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting

Original Article

18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with 18F-FDG and 11C-Methionine PET

Letter to the Editor

Critical considerations on the predictive value of end-of-treatment FDG-PET in lymphoma

Letter to the Editor

The delicate balance between present and future